Development of Immunotherapy for Medullary Thyroid Cancer

甲状腺髓样癌免疫疗法的进展

• 批准号: 10262532
• 负责人: Ravi Madan
• 金额: $ 4.55万
• 依托单位: DIVISION OF BASIC SCIENCES - NCI
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10262532
• 关键词: Cancer Vaccines; Clinical; Clinical Trials; Collaborations; Cooperative Research and Development Agreement; Development; Diagnostic radiologic examination; Disease; Follow-Up Studies; Immune checkpoint inhibitor; Immune response; Immunologics; Immunotherapy; Outcome; Patients; Publications; Therapeutic; Tumor Markers; design; in vivo; medullary thyroid carcinoma; response biomarker; synergism; treatment response; treatment strategy

The project consists of 2 clinical trials each attempting to incite an immune response in patients with Medullary Thyroid Cancer designed to generate an immune response and evaluate clinical outcomes. The first trial involved the use of a therapeutic cancer vaccine that was developed in the NCI as part of CRADA. The second follow-up study involved a collaboration with Merck, evaluating pembrolizumab in patients with Medullary Thyroid Cancer, some of who previously have been treated with cancer vaccine to evaluate immunologic synergies. Both studies are now completed and being prepared for publication

该项目由两项临床试验组成，每一项都试图激发甲状腺髓样癌患者的免疫反应，旨在产生免疫反应并评估临床结果。第一项试验涉及使用 NCI 开发的治疗性癌症疫苗，该疫苗是 CRADA 的一部分。第二项后续研究涉及与默克公司的合作，评估派姆单抗对甲状腺髓样癌患者的疗效，其中一些患者之前曾接受过癌症疫苗治疗，以评估免疫协同作用。这两项研究现已完成并准备发表